We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00742235
Recruitment Status : Completed
First Posted : August 27, 2008
Results First Posted : November 11, 2013
Last Update Posted : April 14, 2016
Information provided by (Responsible Party):
Ishir Bhan, MD, MPH, Massachusetts General Hospital

Brief Summary:
Vitamin D deficiency (low levels of vitamin D in the blood) is a common problem. A recently discovered protein, called hCAP18, likely plays an important role in the immune system and may depend on adequate levels of vitamin D. It is not known what levels of vitamin D are needed to allow the body to make this protein. Nor is it known if giving vitamin D to people who are found to be deficient will help boost levels of hCAP18. This study aims to clarify the relationship between vitamin D levels and hCAP18.

Condition or disease Intervention/treatment
Healthy Subjects Vitamin D Deficiency Drug: ergocalciferol

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 99 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects
Study Start Date : July 2007
Primary Completion Date : January 2012
Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Vitamin D insufficient (treated with ergocalciferol 50,000 IU every other day x 5 doses)
Drug: ergocalciferol
Ergocalciferol 50,000 IU given every other day for 5 total doses
Other Name: Vitamin D
No Intervention: Vitamin D sufficient
Subjects who did not receive ergocalciferol and had a 25-OH vitamin D level >32 ng/ml

Primary Outcome Measures :
  1. hCAP18 Levels [ Time Frame: Baseline ]
  2. Baseline 25-OH Vitamin D Level [ Time Frame: Baseline ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18-80

Exclusion Criteria:

  • Known active infectious disease or chronic inflammatory disorder
  • Hypercalcemia
  • Chronic kidney disease
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00742235

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Ishir Bhan, MD MPH Massachusetts General Hospital

Responsible Party: Ishir Bhan, MD, MPH, Instructor in Medicine, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00742235     History of Changes
Other Study ID Numbers: 2008-P-0003000/1
First Posted: August 27, 2008    Key Record Dates
Results First Posted: November 11, 2013
Last Update Posted: April 14, 2016
Last Verified: March 2016

Additional relevant MeSH terms:
Vitamin D Deficiency
Deficiency Diseases
Nutrition Disorders
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents